Haemonetics Corporation (HAE)

Haemonetics (HAE) is anticipated to report a year-over-year decline in earnings but higher revenues for the quarter ended June 2026. The Zacks Consensus Estimate for EPS is $1.07, down 2.7% from the prior year, with revenues expected to be $327.95 million, up 2%. The company's Earnings ESP is -4.67% and it holds a Zacks Rank of #4, making it difficult to confidently predict an earnings beat.

Robert W. Baird has raised its price target for Haemonetics (NYSE:HAE) to $119 from $96, maintaining an "outperform" rating, which suggests a potential upside of 9.74%. This positive forecast aligns with a broader "Moderate Buy" consensus among analysts, with Haemonetics also reporting strong quarterly earnings that surpassed expectations. Institutional ownership in the medical instruments supplier is significant, with 99.67% of shares held by such investors.

Nierenberg Investment Management Company LLC has acquired 26,280 shares of Haemonetics Corporation (NYSE:HAE) valued at approximately $1.97 billion, making it their 15th largest holding. This acquisition comes amid positive investor sentiment for Haemonetics, driven by a new supply agreement with CSL Plasma, strong quarterly results with raised revenue-growth forecasts, and recent analyst upgrades. The company's stock opened at $108.39, near its 12-month high, while analysts maintain a "Moderate Buy" consensus rating with an average price target of $95.00.

Haemonetics Corp (NYSE:HAE) stock has reached a new 52-week high of $106.64, driven by a 92.73% 1-year return and strong recent performance. This surge follows robust fiscal first-quarter results that surpassed analyst expectations and a new supply agreement with CSL Plasma Inc. Despite this, InvestingPro analysis indicates the shares may be overvalued, though six analysts have revised earnings estimates upwards for the upcoming period.

Aurora Investment Counsel recently acquired a new position in Haemonetics Corporation (NYSE:HAE), purchasing 25,501 shares valued at approximately $1.9 million. This investment comes as Haemonetics has exceeded quarterly expectations, with management raising its full-year revenue-growth outlook, and analysts maintaining a "Moderate Buy" consensus rating for the stock. The company also recently signed a new supply agreement with CSL Plasma, further bolstering positive sentiment.